Dosage and duration of medication for men with lower urinary tract symptoms: two questions without definitive answers.
OBJECTIVE
In this review, the dosage and duration of medication in the management of benign prostatic hyperplasia are discussed. There is no official guideline, however, and even no professional agreement on these points.


RESULTS
Considering the dosage, dose-titration is probably not a drawback as there is a high risk of undertreatment or overtreatment when using a single dosage for every patient. Duration of treatment is a matter of concern. A quarter of patients discontinue their treatment early. For the others, a long period of treatment may be mandatory for those patients who are at risk of progression. After a course of medication (6 months to 1 year), a trial without treatment may help to decide whether treatment must be continued if symptoms relapse.


CONCLUSIONS
For men with lower urinary tract symptoms, there seems to be no definitive answer about the appropriate dosage and duration of medicine.
Desgrandchamps
François
F
Department of Urology, Hopital Saint-Louis, Paris, France. francois.desgrandchamps@sls.ap-hop-paris.fr
Mongiat-Artus
Pierre
P
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013256:Steroids / Q000008:administration & dosage*
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D013256:Steroids